Redmond, Washington. – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that it has secured additional new financing of up to $50.0 million, led by CRG (formerly Capital Royalty L.P.) and existing EGS investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, Foundation Medical Partners, and Radius Ventures.
“EGS has demonstrated that the strong data and dramatic shifts in healthcare economics support increased access to their proprietary TIF® procedure using EsophyX® technology,” said Charles Tate, Chairman of CRG. “Our investment in their business will support growth and build substantial value in…
Read More »CRG Joins Existing Investors In New Financing Deal In Support Of Commercialization Plans
Redmond, Washington. – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that it has secured additional new financing of up to $50.0 million, led by CRG (formerly Capital Royalty L.P.) and existing EGS investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, Foundation Medical Partners, and Radius Ventures.
“EGS has demonstrated that the strong data and dramatic shifts in healthcare economics support increased access to their proprietary TIF® procedure using EsophyX® technology,” said Charles Tate, Chairman of…
Read More »Financing to Support Commercialization of First-in-Class Products for TransCarotid Artery Revascularization (TCAR) Procedure
Sunnyvale, Calif., Oct. 20, 2015 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to alleviating the devastating burden of stroke through surgical innovation, today announced it has received up to $57 million in equity and debt funding from new and existing investors. CRG, a premier healthcare investment firm and a new investor in Silk Road Medical, led the debt financing and also participated as an equity investor alongside returning investors Warburg Pincus and The Vertical Group.
Silk Road Medical's ENROUTE® Transcarotid Neuroprotection System (NPS) and ENROUTE® Transcarotid Stent System…
Read More »HOUSTON, TX, October 19, 2015 – CRG, a healthcare-focused investment firm delivering pioneering growth capital solutions to the global healthcare market, announced today that Scott Li has joined the firm as a Principal in CRG’s New York office.
Mr. Li brings over a decade of healthcare industry financing experience, having served as an advisor, investor and executive to a range of healthcare products, technology and services businesses. Most recently, Mr. Li was a Vice President with Hammond Hanlon Camp LLC (“H2C”), where he advised on M&A engagements for healthcare services clients.
Prior to joining H2C, Mr. Li was…
Read More »San Diego, September 28, 2015 – GenomeDx Biosciences announced today that it has secured expansion financing from CRG, a premier healthcare investment firm, in the form of a senior secured term loan.
“We are pleased to have the support of CRG, an investment partner renowned for its strategic investments in healthcare,” said Doug Dolginow, CEO of GenomeDx. “This financing provides us with the opportunity to further our strategic growth initiatives and enables further commercial expansion of our Decipher® franchise of genomic solutions.”
“We believe that GenomeDx’s application of genomics to solving clinical challenges in oncology is second-to-none,” said…
Read More »-- Financing to Support Commercial Launch of Pantheris™ --
Redwood City, California, September 23, 2015 – Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, announced today that it has entered into a term loan agreement and a securities purchase agreement with CRG (formerly Capital Royalty L.P.). The agreements provide Avinger with new financing of up to $55.0 million.
Under the terms of the term loan agreement, Avinger initially borrowed $30.0 million, which requires…
Provides up to $30 Million in Additional Borrowing Capacity
Santa Rosa, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (NASDAQ:TRIV), manufacturer of the Ovation Prime® Abdominal Stent Graft System, and Capital Royalty Partners II L.P. and its affiliate funds (CRG) announced that they have amended the existing term loan agreement under which TriVascular previously borrowed $50 million.
The transaction primarily amends the terms of the existing term loan agreement with CRG to increase the borrowing amount up to $95.0 million, net of financing fees. The Company continues to have the option to access up to $15.0…
Read More »
Cleveland, June 30, 2015 — ViewRay™, makers of MRIdian™, the world’s first and only clinical MRI-guided radiation therapy system, announced today that the company has secured up to $50 million in debt financing from CRG (formerly Capital Royalty L.P.), a premier healthcare investment firm.
This debt is part of ViewRay’s comprehensive financing strategy to optimize its capital structure and to provide the funding for driving its global expansion. Through the transaction with CRG, ViewRay will initially access $30 million of debt, which is interest only for three…
Read More »Financing To Support Commercial Launch and Ongoing Clinical Trials for Expanded Indications
San Jose, Calif. – June 9, 2015 – Outset Medical, a company focused on reimagining the experience of dialysis care for patients with kidney disease, today announced $91 million in equity and debt funding. New investor Fidelity Research and Management Company led the $51 million equity financing, with participation from existing investors Warburg Pincus and The Vertical Group, as well as new investors Partner Fund Management LP, Perceptive Advisors and CRG. In addition, CRG led a $40 million debt financing.
Outset Medical’s Tablo™ System is…
Read More »Specialty Australasian pharmaceutical sales and development company, AFT Pharmaceuticals Ltd (AFT), has finalised a follow-on equity capital raise with CRG (formerly Capital Royalty L.P.), Atkinson family, AFT board members, and a group of specialist pharma investors from the United States.
The details of the financing are as follows:
An additional US$7.5M in equity has been invested in AFT.
AFT’s founders, Atkinson Family interests, will retain almost 87% ownership of the company going forward. CRG will increase its existing shareholding to almost 9%.
Additional investment from the AFT board and specialist USA based pharmaceutical experts rounded out…
Read More »MENLO PARK, Calif., May 7, 2015 -- Ceterix Orthopaedics today announced that it has entered into a term loan agreement with CRG and certain of its affiliate funds, providing Ceterix with up to $35 million of available borrowing capacity.
"We are excited to have further support to continue our mission to save the meniscus and improve the lives of patients suffering from knee injuries," said John McCutcheon, President and CEO of Ceterix Orthopaedics. "This flexible financing will allow us to continue expanding the possibilities of meniscus repair through additional investment in innovation and clinical research."
San Diego, March 5, 2015 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced that it has entered into a term loan agreement (the "Agreement") with CRG and certain of its affiliate funds. The Agreement provides TearLab with up to $35 million of available borrowing capacity.
Under the terms of the Agreement, CRG will initially provide $15 million. Up to $20 million of additional funding will be available to TearLab, at its option, through September 2016, subject to the satisfaction of certain revenue milestones and other borrowing conditions. The Agreement has a term of six years and…
Read More »
HOUSTON, TX, January 9, 2015 – Capital Royalty L.P. announced today a corporate name change and rebranding of its firm to “CR Group” or “CRG.” The new name is intended to honor Capital Royalty’s heritage and reputation earned over the past decade while more accurately reflecting the growth and expansion of its business to encompass a broad range of structured debt and equity growth capital solutions to emerging healthcare companies.
“Our firm has experienced dramatic growth and investing momentum over the past five…
Read More »